

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
1 July 2004 (01.07.2004)

PCT

(10) International Publication Number
WO 2004/054974 A2

(51) International Patent Classification⁷: **C07D 211/00**

(21) International Application Number:
PCT/US2003/039644

(22) International Filing Date:
12 December 2003 (12.12.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/433,634 13 December 2002 (13.12.2002) US

(71) Applicant (for all designated States except US):
SMITHKLINE BEECHAM CORPORATION
[US/US]; One Franklin Plaza, Philadelphia, PA PA
(US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **KAZMIERSKI, Wieslaw, Mieczyslaw** [US/US]; GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US). **AQUINO, Christopher, Joseph** [US/US]; GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US). **BIFULCO, Neil** [US/US]; GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US). **BOROS, Eric, Eugene** [US/US]; GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US). **CHAUDER, Brian, Andrew** [CA/US]; GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US). **CHONG, Pek, Yoke** [MY/US]; GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US). **DUAN, Maosheng** [CN/US]; GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US). **DEANDA, JR., Felix** [US/US]; GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US). **KOBLE, Cecilia, Suarez** [VE/US]; GlaxoSmithKline, Five Moore Drive, PO Box 13398,

Research Triangle Park, NC 27709 (US). **MCLEAN, Ed, Williams** [US/US]; GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US). **PECKHAM, Jennifer, Poole** [US/US]; GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US). **PERKINS, Angilique, C** [US/US]; GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US). **THOMPSON, James, Benjamin** [US/US]; GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US). **VANDERWALL, Dana** [US/US]; GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US).

(74) Agents: **LEVY, David, J et al.**; GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CCR5 ANTAGONISTS AS THERAPEUTIC AGENTS

(57) Abstract: The present invention relates to compounds of formula (I) or pharmaceutically acceptable derivatives thereof, useful in the treatment or prophylaxis of CCR5-related diseases and disorders, for example, in the inhibition of HIV replication, the prevention or treatment of an HIV infection, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS).

WO 2004/054974 A2

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
1 July 2004 (01.07.2004)

PCT

(10) International Publication Number
WO 2004/054974 A3

(51) International Patent Classification⁷: **A61K 31/46**,
31/445, C07D 451/04, A61P 31/18

(21) International Application Number:
PCT/US2003/039644

(22) International Filing Date:
12 December 2003 (12.12.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/433,634 13 December 2002 (13.12.2002) US

(71) Applicant (for all designated States except US):
SMITHKLINE BEECHAM CORPORATION
[US/US]; One Franklin Plaza, Philadelphia, PA PA
(US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **KAZMIERSKI**,
Wieslaw, Mieczyslaw [US/US]; GlaxoSmithKline, Five
Moore Drive, PO Box 13398, Research Triangle Park, NC
27709 (US). **AQUINO, Christopher, Joseph** [US/US];
GlaxoSmithKline, Five Moore Drive, PO Box 13398,
Research Triangle Park, NC 27709 (US). **BIFULCO, Neil**
[US/US]; GlaxoSmithKline, Five Moore Drive, PO Box
13398, Research Triangle Park, NC 27709 (US). **BOROS**,
Eric, Eugene [US/US]; GlaxoSmithKline, Five Moore
Drive, PO Box 13398, Research Triangle Park, NC 27709
(US). **CHAUDER, Brian, Andrew** [CA/US]; Glaxo-
SmithKline, Five Moore Drive, PO Box 13398, Research
Triangle Park, NC 27709 (US). **CHONG, Pek, Yoke**
[MY/US]; GlaxoSmithKline, Five Moore Drive, PO Box
13398, Research Triangle Park, NC 27709 (US). **DUAN**,
Maosheng [CN/US]; GlaxoSmithKline, Five Moore
Drive, PO Box 13398, Research Triangle Park, NC 27709
(US). **DEANDA, JR., Felix** [US/US]; GlaxoSmithKline,
Five Moore Drive, PO Box 13398, Research Triangle
Park, NC 27709 (US). **KOBLE, Cecilia, Suarez** [VE/US];
GlaxoSmithKline, Five Moore Drive, PO Box 13398,
Research Triangle Park, NC 27709 (US). **MCLEAN, Ed**,
Williams [US/US]; GlaxoSmithKline, Five Moore Drive,

PO Box 13398, Research Triangle Park, NC 27709 (US).
PECKHAM, Jennifer, Poole [US/US]; GlaxoSmithKline,
Five Moore Drive, PO Box 13398, Research Triangle Park,
NC 27709 (US). **PERKINS, Angilique, C** [US/US]; Glaxo-
SmithKline, Five Moore Drive, PO Box 13398, Research
Triangle Park, NC 27709 (US). **THOMPSON, James**,
Benjamin [US/US]; GlaxoSmithKline, Five Moore Drive,
PO Box 13398, Research Triangle Park, NC 27709 (US).
VANDERWALL, Dana [US/US]; GlaxoSmithKline, Five
Moore Drive, PO Box 13398, Research Triangle Park, NC
27709 (US).

(74) Agents: **LEVY, David, J et al.**; GlaxoSmithKline, Five
Moore Drive, PO Box 13398, Research Triangle Park, NC
27709 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR,
CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN,
MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU,
SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE,
SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

(88) Date of publication of the international search report:
2 September 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS



(57) Abstract: The present invention relates to compounds of formula (I) or pharmaceutically acceptable derivatives thereof, useful in the treatment or prophylaxis of CCR5-related diseases and disorders, for example, in the inhibition of HIV replication, the prevention or treatment of an HIV infection, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS).

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 03/39644

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/46 A61K31/445 C07D451/04 A61P31/18

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data, BEILSTEIN Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 99/04794 A (OATES BRYAN ; FINKE PAUL E (US); MACCOSS MALCOLM (US); MERCK & CO INC) 4 February 1999 (1999-02-04) page 103, line 12 - line 17; claims 1,15,18,20	1-61
Y	WO 00/38680 A (EDWARDS MARTIN PAUL ; PRICE DAVID ANTHONY (GB); PFIZER LTD (GB); WOOD) 6 July 2000 (2000-07-06) page 27, line 10; claims 1,2,5-20	1-61
A	WO 02/079190 A (COOPER DAVID GWYN ; FORBES IAN THOMSON (GB); GRIBBLE ANDREW DERRICK (G) 10 October 2002 (2002-10-10) page 12, line 1 - line 3; claim 1; table 1 ----- -/--	1-61



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

* & * document member of the same patent family

Date of the actual completion of the international search

4 June 2004

Date of mailing of the international search report

25.06.04

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Seymour, L

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 03/39644

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98/25605 A (SPRINGER MARTIN S ; MACCOSS MALCOLM (US); MERCK & CO INC (US); MILLS S) 18 June 1998 (1998-06-18) page 61, line 5 - line 11; claims 1,11 page 16 - page 34	1-61
X	US 5 340 822 A (EMONDS-ALT XAVIER ET AL) 23 August 1994 (1994-08-23) column 1, line 11 - line 24; claim 1; examples 22-24	1-23, 25-28, 52-54, 59,60
X	BE 601 228 A (JANSSEN PHARMACEUTICA) 1961 page 2, line 23 - line 27; claim 1 page 9, line 10 - page 28, line 10	1-23, 25-28,54
X	US 2 773 870 A (BILL ELPERN) 11 December 1956 (1956-12-11) column 1, line 20 - line 61 examples	1-23, 25-28,54
X	US 3 539 580 A (HERMANS HUBERT KAREL FRANS ET AL) 10 November 1970 (1970-11-10) column 1, line 13 - line 15; claims 1,5-7 table	1-23, 25-28,54
X	US 3 334 106 A (BIEL JOHN H) 1 August 1967 (1967-08-01) the whole document	1-23, 25-28,54
X	REHSE K ET AL: "Platelet aggregation inhibiting and anticoagulant effects of oligoamines, 1: N-(4-piperidiny1)methanamines" ARCHIV DER PHARMAZIE, VCH VERLAGSGESELLSCHAFT MBH, WEINHEIM, DE, vol. 319, no. 319, 1986, pages 505-515, XP001085385 ISSN: 0365-6233 the whole document	1,25-28, 52-54, 59,60
X	STEVENTON ET AL: "4,4-disubstituted Piperidine High-Affinity NK1 Antagonists: Structure-Activity Relationships and in Vivo Activity" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 41, no. 23, 1998, pages 4623-4622, XP002173109 ISSN: 0022-2623 the whole document	1,25-28, 54

-/-

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 03/39644

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2 248 018 A (OTTO EISLEB) 1 July 1941 (1941-07-01) column 1, line 52 - line 55; claim 6; examples 3,4 -----	1,25-28, 54
X	WO 98/25604 A (SPRINGER MARTIN S ; MACCOSS MALCOLM (US); MERCK & CO INC (US); MILLS S) 18 June 1998 (1998-06-18) page 30, line 26 - line 30 page 34, line 1 - line 22 page 55 - page 85; claim 1 -----	1,7-12, 20,25-61
X	DATABASE WPI Section Ch, Week 200335 Derwent Publications Ltd., London, GB; Class B02, AN 2003-367209 XP002283279 -& JP 2002 348288 A (ONO PHARM CO LTD) 4 December 2002 (2002-12-04) abstract -----	1,7-12, 20,25-61

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 03/39644

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 42-53 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

see additional sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claims 42-53 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box I.2

Claims Nos.: -

The initial phase of the search revealed a very large number of documents relevant to the issue of novelty. So many documents were retrieved that it is impossible to determine which parts of the claims may be said to define subject-matter for which protection might legitimately be sought (Article 6 PCT). For these reasons, a meaningful search over the whole breadth of the claims is impossible. Consequently, the search has been restricted to compounds according to claim 3 for invention 1. For invention 2, a selection of novelty-destroying documents disclosing spiro fused CCR5 modulators have been cited.

In addition, the present claims do not meet the requirements of Article 6 PCT in that the matter for which protection is sought is not clearly defined. The term "pharmaceutically acceptable derivative" does not enable the skilled person to determine which technical features are necessary to perform the stated function. It is thus unclear which specific compounds fall within the scope of said claim. A lack of clarity within the meaning of Article 6 PCT arises to such an extent as to render a meaningful search of the claims impossible. Consequently, the search does not include "pharmaceutically acceptable derivatives" of the compounds of formula I.

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be overcome.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

US 03/39644

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9904794	A	04-02-1999	AU 8576098 A	16-02-1999
			CA 2296314 A1	04-02-1999
			EP 1003514 A1	31-05-2000
			JP 2002510327 T	02-04-2002
			WO 9904794 A1	04-02-1999
			US 6136827 A	24-10-2000
WO 0038680	A	06-07-2000	AU 769449 B2	29-01-2004
			AU 1290400 A	31-07-2000
			AU 763644 B2	31-07-2003
			AU 1675100 A	31-07-2000
			BG 105709 A	28-02-2002
			BG 105721 A	28-02-2002
			BR 9905977 A	14-01-2003
			BR 9916585 A	16-10-2001
			BR 9917007 A	30-10-2001
			CA 2292984 A1	23-06-2000
			CA 2350073 A1	06-07-2000
			CA 2350573 A1	06-07-2000
			CN 1331691 T	16-01-2002
			CN 1331591 T	16-01-2002
			CZ 20012297 A3	11-09-2002
			CZ 20012298 A3	11-09-2002
			EE 200100344 A	15-10-2002
			EE 200100345 A	16-12-2002
			EP 1013276 A1	28-06-2000
			EP 1140920 A1	10-10-2001
			EP 1140085 A1	10-10-2001
			HR 20010468 A1	28-02-2003
			HR 20010478 A1	30-06-2002
			HU 0104795 A2	29-04-2002
			HU 0104910 A2	28-10-2002
			WO 0039125 A1	06-07-2000
			WO 0038680 A1	06-07-2000
			ID 29031 A	26-07-2001
			ID 28965 A	19-07-2001
			JP 2000212159 A	02-08-2000
			JP 2002533393 T	08-10-2002
			JP 3522691 B2	26-04-2004
			JP 2002533461 T	08-10-2002
			JP 2004099618 A	02-04-2004
			NO 20013149 A	23-08-2001
			NO 20013183 A	08-08-2001
			NZ 511794 A	31-10-2003
			NZ 511796 A	28-11-2003
			PL 349091 A1	01-07-2002
			PL 349495 A1	29-07-2002
			SK 8752001 A3	04-02-2003
			SK 8762001 A3	04-02-2003
			TR 200101793 T2	21-12-2001
			TR 200101867 T2	21-11-2001
			TR 200200938 T2	21-05-2002
			US 6586430 B1	01-07-2003
			ZA 200104211 A	14-01-2002
WO 02079190	A	10-10-2002	WO 02079190 A1	10-10-2002
WO 9825605	A	18-06-1998	AU 5803398 A	03-07-1998

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/US 03/39644

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9825605	A	WO 9825605 A1	18-06-1998
		US 5962462 A	05-10-1999
US 5340822	A	23-08-1994	
		FR 2676055 A1	06-11-1992
		AT 181550 T	15-07-1999
		AU 652046 B2	11-08-1994
		AU 1591692 A	05-11-1992
		BR 9201656 A	15-12-1992
		CA 2067877 A1	04-11-1992
		CS 9201329 A3	18-11-1992
		DE 69229460 D1	29-07-1999
		DE 69229460 T2	20-01-2000
		DK 512901 T3	06-12-1999
		EP 0512901 A1	11-11-1992
		ES 2137176 T3	16-12-1999
		FI 921951 A	04-11-1992
		FI 951242 A	16-03-1995
		FI 951243 A	16-03-1995
		GR 3030755 T3	30-11-1999
		HK 1005138 A1	12-05-2000
		HU 61539 A2	28-01-1993
		IE 921364 A1	04-11-1992
		IL 101760 A	18-02-1997
		IL 117921 A	18-02-1997
		JP 3242980 B2	25-12-2001
		JP 5186425 A	27-07-1993
		KR 258373 B1	01-07-2000
		MX 9202027 A1	01-01-1993
		NO 921734 A ,B,	04-11-1992
		NZ 242586 A	26-10-1995
		RU 2083574 C1	10-07-1997
		US 5770735 A	23-06-1998
		US 5625060 A	29-04-1997
		ZA 9203178 A	27-01-1993
BE 601228	A	NONE	
US 2773870	A	11-12-1956	NONE
US 3539580	A	10-11-1970	
		BE 717143 A	27-12-1968
		CH 485720 A	15-02-1970
		DE 1770604 A1	04-11-1971
		ES 354905 A1	16-11-1969
		FR 7453 M	24-11-1969
		FR 1569475 A	30-05-1969
		GB 1199365 A	22-07-1970
		NL 6808415 A	27-12-1968
US 3334106	A	01-08-1967	NONE
US 2248018	A	01-07-1941	NONE
WO 9825604	A	18-06-1998	
		AU 5604998 A	03-07-1998
		WO 9825604 A1	18-06-1998
		US 6013664 A	11-01-2000
JP 2002348288	A	04-12-2002	NONE